Venous Thromboembolism Taskforce Audit Program

Sponsor
Sanofi (Industry)
Overall Status
Completed
CT.gov ID
NCT00535171
Collaborator
(none)
8,764
1

Study Details

Study Description

Brief Summary

To determine the effect of an interventional campaign run by a dedicated "VTE Nurse Educator" over a 6-month period and the effect on prophylaxis rates.

To determine the proportion of medically admitted patients with risk factors for VTE.

To assess and compare the use of venous thromboembolism (VTE) prophylaxis in hospitalized medical patients versus recommendations and current guidelines.

To determine the patient characteristics of those deemed to be at risk of VTE. To determine the proportion of patients receiving appropriate thromboprophylaxis for their risk.

To determine the type and duration (where possible) of prophylaxis used.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    8764 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Prospective
    Official Title:
    Venous Thromboembolism Taskforce Audit Program
    Study Start Date :
    Jun 1, 2007
    Actual Primary Completion Date :
    Aug 1, 2008

    Outcome Measures

    Primary Outcome Measures

      Eligibility Criteria

      Criteria

      Ages Eligible for Study:
      18 Years and Older
      Sexes Eligible for Study:
      All
      Accepts Healthy Volunteers:
      No
      Inclusion Criteria:
      • Hospital admission for an acute illness with an in-patient hospital stay of 3 days or more.
      Exclusion Criteria:
      • Patients who have undergone any type of surgery during current admission

      • Patients who are admitted to a ward or department that is excluded from this study e.g psychiatric, paediatric, maternity, intensive care unit, coronary care unit.

      • Prior enrollment in this protocol during current admission

      • Prior enrollment in a VTE study involving pharmaceutical or mechanical treatment within last 90 days.

      • Admission for suspected or diagnosed deep vein thrombosis

      The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

      Contacts and Locations

      Locations

      Site City State Country Postal Code
      1 Sanofi-Aventis MacQuarie Park Australia

      Sponsors and Collaborators

      • Sanofi

      Investigators

      • Study Director: Fiona Howard, Sanofi

      Study Documents (Full-Text)

      None provided.

      More Information

      Publications

      None provided.
      Responsible Party:
      , ,
      ClinicalTrials.gov Identifier:
      NCT00535171
      Other Study ID Numbers:
      • DIREG_L_01927
      First Posted:
      Sep 26, 2007
      Last Update Posted:
      Jan 22, 2010
      Last Verified:
      Jan 1, 2010

      Study Results

      No Results Posted as of Jan 22, 2010